|1.||Califf, Robert M: 8 articles (03/2015 - 10/2008)|
|2.||Haffner, Steven M: 7 articles (11/2013 - 10/2008)|
|3.||Holman, Rury R: 6 articles (11/2013 - 10/2008)|
|4.||Kawamori, Ryuzo: 6 articles (06/2012 - 11/2002)|
|5.||Watada, Hirotaka: 5 articles (09/2015 - 08/2004)|
|6.||McMurray, John J V: 5 articles (03/2015 - 04/2010)|
|7.||Tognoni, Gianni: 5 articles (11/2013 - 04/2010)|
|8.||Bethel, M Angelyn: 5 articles (11/2013 - 10/2008)|
|9.||Hirose, Takahisa: 4 articles (09/2015 - 12/2002)|
|10.||Sun, Jie-Lena: 4 articles (03/2015 - 03/2013)|
09/01/2002 - "In sum, nateglinide is a safe and effective therapeutic option for treatment of patients with mild to moderate fasting hyperglycemia."
12/01/2002 - "Nateglinide was safe and effective in reducing postprandial hyperglycemia in subjects with IGT. "
05/01/2014 - "However, nateglinide pretreated i.c.v. did not affect the KA-induced neuronal cell death and hyperglycemia. "
06/01/2005 - "Since postprandial hyperglycemia could be well treated by nateglinide, we examined the background factors of type 2 diabetic patients to determine the optimal indication for nateglinide. "
09/01/2002 - "Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia."
03/01/2006 - "Beneficial effects of nateglinide on insulin resistance in type 2 diabetes."
03/01/2011 - "Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker Fatty rats by suppressing advanced glycation end product receptor axis."
03/01/2006 - "Nateglinide ameliorates insulin resistance as well as insulin secretory defects in type 2 diabetic patients."
03/01/2006 - "The aim of this study is to evaluate the effect of nateglinide on insulin resistance as well as insulin secretory defects in type 2 diabetic patients. "
03/01/2005 - "The aim of this study was to investigate the influence of changes in insulin resistance and early insulin secretion on the insulin secretagogic effects of nateglinide. "
|3.||Type 2 Diabetes Mellitus (MODY)
07/01/2003 - "Results of STOP-NIDDM trial suggest that nateglinide, which attenuates post-prandial glycemic surge in type 2 diabetes, may also be helpful for the protection against cardiovascular events. "
02/01/2005 - "Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography."
06/01/2003 - "Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study."
03/01/2013 - "Nateglinide is commonly used in the treatment of patients with type 2 diabetes mellitus. "
01/01/2010 - "Pharmacokinetics of nateglinide enantiomers and their metabolites in Goto-Kakizaki rats, a model for type 2 diabetes mellitus."
|4.||Hypoglycemia (Reactive Hypoglycemia)
11/01/2005 - "This study was conducted to identify the nature of any adverse effects associated with nateglinide and to evaluate its clinical efficacy in patients with type 2 diabetes, with particular attention to hypoglycemia. "
12/01/2013 - "One of the dangerous side effects of nateglinide administration is rapid hypoglycemia, a condition that needs to be monitored carefully to prevent unnecessary fatalities. "
04/22/2010 - "Nateglinide did, however, increase the risk of hypoglycemia. "
11/01/2005 - "Severe hypoglycemia was recognized in only 1 case of diabetes complicated by serious renal dysfunction, for which nateglinide has been contraindicated in Japan. "
01/01/2005 - "Hypoglycemia following a nateglinide overdose in a suicide attempt."
|5.||Prediabetic State (Prediabetes)
12/01/2014 - "In prediabetes, several well-designed preventive trials have shown that lifestyle and pharmacologic interventions such as metformin, thiazolidinediones (TZD), acarbose and, nateglinide and orlistat, are effective in reducing diabetes development. "
11/01/2005 - "Several drugs having different mechanisms of action, such as metformin, glitazones, acarbose, orlistat, nateglinide, glicazide, angiotensin-converting enzymes, angiotensin receptor blockers have been found to be effective in prediabetes to improve the glycaemic status, though they are still not recommended by any professional organisation."
|7.||Blood Glucose (Blood Sugar)
|1.||Exercise Therapy (Therapy, Exercise)
|2.||Transplantation (Transplant Recipients)